ストックスクリーナーアプリを入手
27.05
1.65%
0.44
前日終値:
$26.61
開ける：
$26.54
24時間の取引高:
52.99M
Relative Volume:
1.13
時価総額：
$153.81B
収益：
$62.58B
当期純損益:
$7.79B
株価収益率:
19.96
EPS:
1.3551
ネットキャッシュフロー:
$9.08B
1週間 パフォーマンス:
-2.17%
1か月 パフォーマンス:
-0.62%
6か月 パフォーマンス:
+8.72%
1年 パフォーマンス:
+3.09%
1日の値動き範囲:
$26.23
$27.13
1週間の範囲:
$26.20
$27.61
52週間の値動き範囲:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.05 | 151.31B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now - The Motley Fool
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union
Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus
Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus
Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN - AASTOCKS.com
China Greenlights Pfizer’s Obesity Injection as Generic Rivals Approach - FXLeaders
Pfizer Secures China Nod for Obesity Drug as Generics Loom - Bloomberg
China approves Pfizer GLP-1 drug for weight management - Yahoo Finance
China approves Pfizer GLP-1 drug for weight loss - Reuters
Pfizer Gets OK For $29M SEC Payout From Insider Case - Law360
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund - Reuters
Pfizer’s Comirnaty Update: What U.S. Patients Need To Know Now - AD HOC NEWS
Pfizer Arbitration Confidentiality Rule Is Lawful, NLRB Says - Law360
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com
Retinal Vein Occlusion Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer - Barchart.com
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - TradingView
Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat
Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat
Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha
Skeletal Dysplasia Market - GlobeNewswire Inc.
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz
Pfizer Arbitration Gag Provision Is Lawful, Labor Board Rules - Bloomberg Law News
Pfizer’s Comirnaty update: what US patients really need now - AD HOC NEWS
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
Pfizer's Portfolio Renewal In ProgressHigh Yields For The Patient (NYSE:PFE) - Seeking Alpha
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
Yeast Infection Treatment Market Is Going to Boom Rapidly | Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A. - openPR.com
ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP - The Manila Times
Pfizer Inc. $PFE Shares Sold by Mcdonald Partners LLC - MarketBeat
Griffith & Werner Inc. Makes New Investment in Pfizer Inc. $PFE - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Acquires 1,579,117 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE:PFE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Finviz
Pfizer (NYSE:PFE) Shares Down 2.4%Here's Why - MarketBeat
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Does New Oncology Data Shift The Pipeline-Driven Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer CEO Has ‘A Problem With CBER Leadership’ At US FDA - Citeline News & Insights
Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value - TipRanks
Pfizer CEO On FDA Vaccines Decisions: ‘We Have A Problem With CBER Leadership’ - Citeline News & Insights
Pfizer stock: Mixed technicals and dividend focus drive a sharp downside move - Traders Union
Pfizer's Quiet Cash Comeback (NYSE:PFE) - Seeking Alpha
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
1.25%
0.53%
大文字化:
|
ボリューム (24 時間):